对于某些非肥胖而口咽部阻塞明显的重度OSA患者，可以考虑在应用CPAP治疗1～2个月、夜间呼吸暂停及低氧已基本纠正情况下施行UPPP手术治疗。术前和术中应严密监测患者的情况，术后必须定期随访，如手术失败，应使用CPAP治疗 [4] 。

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

July 23, 2024 — Nearly 40 million adults in the U.S. have sleep apnea ... 2024 — A new study demonstrates that when individuals with obstructive sleep apnea use their positive airway pressure ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Obstructive sleep apnea (OSA) is associated with an increased risk for cardiovascular disease (CVD) in adults, even those younger than 40 years, according to a study published online June 6 in the ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

The global sleep apnea implants market is expected to grow from USD 317.1 million in 2023 to USD 1,158.1 million by 2033, at ...

Averaging up to 20% of weight loss, adults taking Tirzepatide had at least 25 fewer breathing interruptions each hour as they ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

Between 30-50% of adults with hypertension have OSA, and this number increases to between 70-80% in adults with resistant hypertension. Additionally, untreated moderate-to-severe OSA increases the ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...